CinCor Pharma (CINC) announced the appointment of Michael Kalb as Executive Vice President, EVP, and Chief Financial Officer, CFO, effective November 4. Kalb brings over 25 years of global financial, operations and strategic transactional experience. He is replacing Terry Coelho who is retiring from her role as Executive Vice President, CFO and Chief Business Development Officer. Kalb’s experience includes six years as Chief Financial Officer for Amarin Corporation (AMRN).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CINC:
- CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions
- CinCor Pharma Announces Publication in the New England Journal of Medicine of Phase 2 BrigHtn Data on Selective Aldosterone Synthase Inhibitor Baxdrostat in Treatment-Resistant Hypertension
- Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update
- CinCor Reports Third Quarter Financial Results and Provides Corporate Update
- CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research